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Abstract
Background: The near exclusive use of praziquantel (PZQ) for treatment of human schistosomiasis has raised concerns
about the possible emergence of drug-resistant schistosomes.
Methodology/Principal Findings: We measured susceptibility to PZQ of isolates of Schistosoma mansoni obtained from
patients from Kisumu, Kenya continuously exposed to infection as a consequence of their occupations as car washers or
sand harvesters. We used a) an in vitro assay with miracidia, b) an in vivo assay targeting adult worms in mice and c) an in
vitro assay targeting adult schistosomes perfused from mice. In the miracidia assay, in which miracidia from human patients
were exposed to PZQ in vitro, reduced susceptibility was associated with previous treatment of the patient with PZQ. One
isolate (‘‘KCW’’) that was less susceptible to PZQ and had been derived from a patient who had never fully cured despite
multiple treatments was studied further. In an in vivo assay of adult worms, the KCW isolate was significantly less susceptible
to PZQ than two other isolates from natural infections in Kenya and two lab-reared strains of S. mansoni. The in vitro adult
assay, based on measuring length changes of adults following exposure to and recovery from PZQ, confirmed that the KCW
isolate was less susceptible to PZQ than the other isolates tested. A sub-isolate of KCW maintained separately and tested
after three years was susceptible to PZQ, indicative that the trait of reduced sensitivity could be lost if selection was not
maintained.
Conclusions/Significance: Isolates of S. mansoni from some patients in Kisumu have lower susceptibility to PZQ, including
one from a patient who was never fully cured after repeated rounds of treatment administered over several years. As use of
PZQ continues, continued selection for worms with diminished susceptibility is possible, and the probability of emergence
of resistance will increase as large reservoirs of untreated worms diminish. The potential for rapid emergence of resistance
should be an important consideration of treatment programs.
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Introduction
Schistosomiasis is one of the most common human parasitic
diseases in the world. An estimated total of 207 million persons are
infected worldwide, 97% of which are on the African continent [1].
The chronic and debilitating nature of the disease results in high
costs in public health and economic productivity in developing
countries, and has prompted the initiation of large scale control
programs [2]. Schistosoma mansoni is one of the most common
etiological agents for human schistosomiasis, and is estimated to
infect more than 83 million humans in 54 countries [3].
Praziquantel (PZQ) is the least expensive, easiest to use and
most readily available of all currently available schistosomicides
[4]. It is highly effective against all schistosome species that are
known to infect humans and is well-tolerated, making it suitable
for mass treatment campaigns. These campaigns are particularly
targeted at school-age children who represent the most heavily
infected segment of the population [5,6]. Although such programs
have immediate and significant salutary effects, three general
concerns are that they 1) inevitably leave some individuals
untreated; 2) some individuals are treated but left uncured; and
3) they do not interrupt transmission, making re-infection a reality
[7]. Another major concern of all anthelminthic and antibiotic
drugs is the potential for resistance to develop and spread
throughout the population, making the drug useless for treatment
and control. Even though PZQ efficacy is generally high, reported
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explanations for incomplete cures are use of doses that are actually
sub-curative in people, or the presence of drug resistance traits
present in natural populations of worms.
The extensive use of PZQ for over 20 years in some African
nations has raised concern regarding the selection of drug resistant
worms [5,11–13]. Artificial selection in the laboratory has
produced resistant strains of S. mansoni in only 2 generations of
repeated exposure to sub-lethal doses of the drug in mice [11], thus
demonstrating that resistance is more than a hypothetical
possibility. Low cure rates in response to PZQ in the field
appeared 10–15 years after the beginning of its use on a mass scale
in Egypt and after a recent introduction of the worms in Senegal
[12–16]. In both of these cases, worms from the uncured patients
were also less susceptible to PZQ when tested in a mouse model
[17]. Therefore, traits of the worms themselves led to PZQ failure,
although other factors were also suspected to contribute including
host factors, heavy worm burdens, and pre-patent infections
[13,17]. Reports of difficulties in obtaining cures among travelers
with schistosomiasis [18] further underscore the need to remain
vigilant. Most published discussions of this topic conclude that
convincing evidence for the clinically relevant emergence of PZQ
resistance in the field is still lacking [4,5,16,19,20]. Once drug
resistance reaches clinical relevance it becomes a difficult problem
to solve. Therefore, vigilant monitoring aimed at the prevention of
clinical drug resistance is critical to treatment and control of
infectious diseases.
Measuring the impact of PZQ on adult worms harbored by
human subjects is at best an indirect process in that it relies on the
relatively insensitive method of measuring reduction in schisto-
some egg excretion in treated individuals [21]. Also, several factors
influence PZQ’s effects such as variable pharmacokinetics in
different individuals, differences in immune responses to the
worms, maturity of worms, and genetic variability of the worms
themselves, both among individual hosts and geographic regions
[13,16,20,22,23]. Obtaining an isolate from human patients for
further in vivo tests in laboratory hosts such as mice can address
some of these concerns [13,17] and can be complemented with in
vitro testing that removes host-induced effects. In vitro tests for PZQ
sensitivity have been developed for use on schistosomes [24–26].
Within a given isolate, the susceptibility of miracidia correlates
with the susceptibility of adult worms [26]. Using miracidia in
these assays potentially allows the testing of schistosomes derived
from a large number of human infections.
The aim of this study was to evaluate the level of susceptibility to
PZQ among a natural population of S. mansoni that were derived
from Kenyan car washers and sand harvesters occupationally
exposed to schistosome infection in Lake Victoria. These people
have been enrolled in a longitudinal study designed to investigate
immunologically-based host resistance to S. mansoni re-infection,
and many of the participants have been treated with PZQ on
multiple occasions throughout the study [27–30]. We first used an
in vitro assay with miracidia to evaluate PZQ susceptibility of S.
mansoni from several patients. Then, an isolate of S. mansoni was
established in laboratory hosts from one of the patients, who had
never fully cured after initial or several subsequent PZQ
treatments. The susceptibility of adult worms of this and other
Kenyan isolates and of two laboratory stocks of S. mansoni were
compared using both conventional in vivo trials in mice, and with
an in vitro assay with adult worms.
Materials and Methods
Source of S. mansoni isolates from human subjects
The patient-derived S. mansoni isolates were recovered from eggs
in the fecal samples of adult males working as car washers or sand
harvesters in or near Kisumu, western Kenya. The car washers use
the shallow water along the Lake Victoria shoreline to wash cars
and trucks and so are repeatedly in contact with water in an area
where snails infected with S. mansoni snails have been repeatedly
found [31]. The sand harvesters also experience extensive contact
with lake water as they shovel sand from the submerged lake
bottom into boats, often exposed to water from the chest down for
hours each day. Since June 1995, the car washers have been
continuously enrolled in several longitudinal studies that evaluate
resistance to S. mansoni infection [27–30]. The sand harvesters
were enrolled in similar studies starting in March 2005. For each
patient, information is available regarding intensity of infection
and history of exposure to treatment with PZQ since the time of
their enrollment in these studies. As part of the ongoing work
associated with these studies, fecal samples derived from each
patient are regularly tested for S. mansoni using the modified Kato-
Katz technique. For the purposes of the present study, miracidia
hatched from S. mansoni eggs were used either directly in the PZQ
susceptibility assay for miracidia described below or, in two cases,
were used to establish laboratory isolates.
S. mansoni isolates propagated in the laboratory for
further study
Miracidia obtained from eggs in positive fecal samples from
individual patients were used to establish the following isolates in
laboratory raised B. sudanica and six to eight week old outbred
mice:
KCW: The KCW isolate was established from a car washer who
had received 18 PZQ treatments since the beginning of the study.
Following initial and all subsequent treatments, egg counts in this
patient had never fallen to zero [28], suggesting the responsiveness
of worms from this patient to PZQ was worthy of further study. At
the second generation, this isolate was divided and maintained as
separate ‘‘sub-isolates’’ in New Mexico and in Kenya. Worms of
Author Summary
The emergence of drug resistant pathogens is a great
challenge to the control of infectious diseases. Schistoso-
miasis is one of the world’s greatest neglected tropical
diseases, and it is primarily controlled with the drug
praziquantel. This drug is often used by repeatedly
treating patients to maintain reduced worm burdens, an
ideal situation to encourage the evolution of resistant
worms. Although drug based control programs are
increasing, monitoring efforts for drug resistance remain
rare. We measured drug susceptibility of schistosomes
from a cohort of patients in Kenya who are enrolled in a
longitudinal study in which they are repeatedly treated
with praziquantel. We found that schistosomes from
previously treated patients were significantly less suscep-
tible than those that were not. Also, schistosomes derived
from a single patient who had been treated with
praziquantel 18 times showed marked resistance. Al-
though the findings of this study indicated that reduced
drug susceptibility occurs in this population of schisto-
somes, this trait does not seem to be spreading widely or
creating clinical levels of resistance. We hypothesize that
the trait remains at low frequency because of the large
population of schistosomes that are not exposed to the
drug and/or potential fitness costs associated with
reduced susceptibility.
Praziquantel Tolerance in Schistosomes
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unless otherwise noted.
KSH: The KSH isolate was established from a sand harvester
who had never been treated with PZQ prior to this study.
KAS: This isolate was established from a human fecal sample
collected near a stream (Asao) about 38 Km south east from
Kisumu in 2006 (20.33256uS, 34.99914uE).
KNY: The KNY isolate was established from cercariae obtained
from B. sudanica collected in Nyabera marsh (20.10971uS,
34.77461uE) on the outskirts of Kisumu on the road to Ahero.
Both KAS and KNY isolates were from areas not previously
included in PZQ treatment campaigns of local school children.
In addition to the isolates obtained from Kenya patients, the
following isolates were used for comparison:
PR1: This laboratory stock is originally of Puerto Rican origin.
It has been maintained in the laboratory, including at the
University of New Mexico, for more than 20 years.
NMRI: This laboratory stock also originated from Puerto Rico
and has been maintained at the Biomedical Research Institute,
Rockville, Maryland (www.afbr-bri.com).
In vitro assay to ascertain susceptibility of miracidia to
PZQ
To test the idea that miracidia derived directly from different
patients may differ in their susceptibility to PZQ, particularly
given that some patients (see KCW above) had never fully cured
following treatment with PZQ, we employed a modified version of
the in vitro technique developed by Liang et al. [26]. Freshly
hatched miracidia from the stools of sand harvesters (n=14) and
car washers (n=9) were placed in each well (3–6 miracidia in each
well) in a 96-well plate in 40 ml of aged tap water. Each row of the
plate (one group of miracidia) received a different concentration of
PZQ: 0 M (control), 10
25 M, or 10
26 M, in a 40 ml volume. PZQ
was prepared as a stock solution of 10
24 M in 1% DMSO, and the
final concentration of DMSO was 0.1% in all wells including the
control wells. The mean number of groups of miracidia used per
patient per concentration of PZQ was 10.2 (range: 4–12)
(dependent on the number of miracidia obtained from a fecal
sample). This design was repeated with miracidia from three
different fecal samples from each patient. Miracidia were observed
with the aid of a dissecting microscope prior to, 10 min and
20 min after addition of PZQ, and the observer had no knowledge
of the PZQ concentration of each well. The number of miracidia
that were alive and dead in each well was recorded. Miracidia
were considered dead if they remained immobile. We present only
results using 10
25 M at the 20 min observation time to simplify
the presentation and because they are representative of the
combinations of observation times (10 or 20 minutes) and PZQ
concentrations (10
25 M, or 10
26 M) used. A Generalized
Estimating Equations (GEE) approach was used to fit a logistic
regression model to the data using the Proc GENMOD procedure
in SAS 9.1. Separate models were fit for each concentration of
PZQ (0 M, 10
26 M and 10
25 M). The number of previous PZQ
treatments the subjects received was included in the model using
an indicator variable that was set to ‘1’ if a patient had received no
previous treatments, and‘0’ for patients who had received one or
more previous treatments, and the time of exposure to the drug in
vitro (0, 10 or 20 min).
In vivo assay to ascertain susceptibility of adult worms to
PZQ
For each isolate of S. mansoni examined, 10 to 30 outbred mice
were infected with 200 cercariae per mouse. Seven and a half
weeks after exposure, mice were randomly divided into two
groups, one of which was given 1000 mg/kg PZQ dissolved in 2%
Cremaphor EL over 4 consecutive days (250 mg/kg per day). This
dose was chosen because it will achieve a parasite reduction of at
least 95% in mice [32]. The other group was given only the vehicle
(2% Cremaphor EL) as a control. Two weeks after treatment, mice
from both groups were euthanized and perfused with RPMI
medium [33]. The body cavity, liver, and mesenteric veins were
examined for worms after perfusion to ensure all worms were
found. This assay was repeated two more times with subsequent
generations of the KCW isolate, three more times for the PR1
isolate, and once more for both the NMRI and KNY isolates. We
were unable to perpetuate the KAS isolate due to difficulties in
hatching the eggs obtained from infected mice and to establish
snail infections, making further experiments with it impossible.
To eliminate the possibility that low PZQ susceptibility was due
to a longer development time of the KCW worms, an additional in
vivo assay was performed in which treatment was given at two time
points. Mice were exposed to S. mansoni, randomly divided into 3
groups, and treatment was administered at either 7.5 or 10.5
weeks after exposure. The control group received the sham
treatment at 7.5 weeks post exposure. Immature worms are not
susceptible to PZQ, and studies of the NMRI isolate indicated that
susceptibility corresponds to the onset of reproductive develop-
ment at 6 to 7 weeks post infection [34].
The sub-isolate of KCW that was kept at the Kenya Medical
Research Institute (KEMRI) was tested for PZQ sensitivity in vivo
after 3 years of passages in the absence of drug pressure or testing.
Mice infected with this subset of KCW were treated at 10 weeks
post-exposure, following the above protocol.
The efficacy of treatment (ET) with PZQ as applied to the
different isolates was measured as the percent of reduction of
worm burdens based on the numbers recovered using the formula
[35]:
% Worm burden reduction~
Mean#worms from control group ðÞ { Mean#worms from treated group ðÞ
Mean#worms from control group
|100
The number of worms recovered from the treated and control
groups were compared across S. mansoni isolates with a randomized
Generalized Linear Model 2-way ANOVA after log transforma-
tion of worm counts with SAS 9.1. The main factors considered
were S. mansoni isolate, and treatment; 2-way interactions among
the main factors were analyzed.
In vitro assay to ascertain susceptibility of adult worms to
PZQ
To complement the in vivo mouse treatment results an in vitro
assay was devised to assess susceptibility of adult worms of S.
mansoni to PZQ. Adult worms exposed to PZQ immediately
contract. Although the mechanism by which PZQ causes this
contraction is not fully understood, it is accompanied by a rapid
influx of calcium ions, a slower influx of sodium ions and a
decreased influx of potassium ions [36]. The rationale of our assay
was to use the degree of contraction and subsequent recovery from
contraction as a measure of PZQ susceptibility. We compared the
length of the worms before exposure, during exposure (when the
worms are contracted), and after a 24 hour recovery period to
allow surviving worms to regain their normal lengths. Survival
rates were also determined.
Adult male worms (KCW, KNY and PR1, and the sub-isolate
of KCW maintained in Kenya) were recovered by perfusion of
Praziquantel Tolerance in Schistosomes
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CO2, in RPMI medium supplemented with 20% Fetal Bovine
Serum, 100–500 IU Penicillin, and 100 mg/ml Streptomycin.
Overnight incubation allowed for recovery from the stress caused
by the perfusion. A single worm was placed in each well of a 96-
well plate in 180 ml of supplemented RPMI medium. Before
exposure to PZQ, each worm was photographed with a Nikon
Coolpix 4500 camera mounted on a dissecting microscope
phototube with a Thales Optem digital camera adapter. Then,
20 ml of either the control medium or a PZQ solution, of five
different concentrations, was added to each well, resulting in final
concentrations of 0, 0.8, 8.0, 80.0, 400.0, and 800.0 mg/ml. The
control solution contained 0.1% DMSO, the same concentration
as that in the experimental wells. The worms were incubated in
the PZQ solution at 37uC for 3 hours and then photographed.
The medium in each well was removed; the worms were washed
three times, and were then transferred to a new 96-well plate in
fresh RPMI medium, and held at 37uC. Each worm was re-
photographed at the end of the 24 hour recovery period.
The images of the worms before treatment and after recovery
were processed with Metamorph v.4.65 software using the ‘‘fiber
length’’ option which measures the object’s length. The length of
the worms was compared across S. mansoni isolates and PZQ
concentrations and analyzed statistically with SAS 9.1 with a
randomized ANOVA design; this was followed by Tukey’s
multiple comparisons to find significant pair-wise differences.
This research project has been reviewed and approved by the
University of New Mexico’s Institutional Animal Care and Use
Committee (IACUC), and the institutional review boards of the
University of Georgia and the Centers for Disease Control and
Prevention, the Scientific Steering Committee of the Kenya
Medical Research Institute, and the KEMRI/National Ethics
Review Board of Kenya. All investigators/assistants in this study
have attained animal use certification regarding the ethical
treatment of animals.
Results
In vitro effects of PZQ on miracidia derived from different
patients
As expected, the in vitro effect of PZQ on the survival odds of
miracidia was significantly influenced by drug concentration and
time of exposure. To simplify data presentation, we show the
results of exposure of miracidia derived from 23 different patients
to 10
25 M PZQ after 20 minutes (Figure 1). For all time points
examined, all miracidia held in water without PZQ continued to
swim normally. There was considerable variation among the
miracidia derived from different patients with respect to
susceptibility to PZQ. The logistic regression model indicated
that the odds of survival of miracidia in the in vitro assay upon
exposure to 10
25 M PZQ are increased among those from
patients who had received previous treatment compared to those
from patients who had never been treated. Specifically, we
obtained an estimated odds ratio of 2.42 [with a corresponding
95% confidence interval of (1.94, 3.01)] for comparing survival of
miracidia in a previously-treated versus untreated group. In other
Figure 1. In vitro efficacy of 10
25 M PZQ in killing S. mansoni miracidia after 20 minutes of exposure in 96 well plates. Miracidia were
hatched from fecal samples collected from human patients from the Kisumu area in Kenya, and the assay run in triplicate. The percentage of miracidia
dead at the end of the 20 min observation period is graphed. Error bars correspond to standard error of the mean. Numbers above bars correspond
to number of PZQ treatments. Data for parasites obtained from sand harvesters are indicated by squares and circles for car washers.
doi:10.1371/journal.pntd.0000504.g001
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for miracidia collected from individuals who were previously
treated than for those collected from patients who had never
before been treated.
Miracidia obtained from the car washer who had never fully
cured following treatment and from whom the KCW isolate was
derived were among the least susceptible to PZQ (# 22, Figure 1).
We then passaged an isolate from a patient who had never been
treated (KSH) and the KCW isolate through snails and mice in the
lab and tested miracidia from the mice to determine their PZQ
susceptibility. KCW miracidia were significantly less susceptible
(p,0.05) to PZQ (11% miracidia killed, from 6 trials) than KSH
miracidia (75% miracidia killed, from 2 trials), suggesting that the
reduced PZQ susceptibility of KCW was a heritable trait.
In vivo effects of PZQ on adult worms in mouse infections
With subsequent mouse infections we compared the PZQ
susceptibility of adults of the KCW isolate with adults from other
Kenyan isolates (KAS and KNY) or from long-maintained
laboratory stocks (PR1 and NMRI).
The results (Figure 2) are summarized based on multiple
independent trials performed on successive generations of the
worms, except for KAS, for which we had data from only one trial.
The worm yields obtained from mice varied among isolates, which
is not surprising given that the Kenyan isolates were recently
derived from humans whereas the PR1 and NMRI isolates have
been maintained in mice for decades. However, by reference to
worm recoveries from corresponding untreated controls, we
concluded that the efficacy of treatment was significantly lower
in mice infected with KCW (31.3%) than in mice infected with S.
mansoni from the other 4 sources (over 98% for PR1, NMRI, and
KNY and 67.8% for KAS; p,0.05), using a randomized ANOVA
design. It should be noted that while the sex ratio for the worms
recovered from mice infected with the KCW strain was male
biased, the infections were not predominantly single sexed.
Due to low infectivity for snails and mice and the inevitable
attendant loss of genetic diversity, KAS worms recovered from
mice were mostly or only males. The relatively low efficacy of
treatment in mice infected with the KAS isolate (67.8%) might be
explained by this phenomenon, since worms from single-sex
infections are less susceptible to PZQ than those from mixed-sex
infections [24].
The results of the in vivo trial to examine the effects of delayed
maturation showed that the efficacy of treatment was 28.1% at 7.5
weeks post-exposure and 26.3% at 10.5 weeks post-exposure. The
mean number of worms recovered from control and treated mice
did not differ significantly at either 7.5 weeks post-exposure
(control 32.067.9, treated 23.066.0, p=0.39) or 10.5 weeks post-
Figure 2. Average number of S. mansoni adult worms perfused from mice, following treatment with 1000 mg/kg of PZQ in
Cremaphor 2% EL. Treatment was administered at 7.5 weeks p.i., and mice perfused 2 weeks after treatment. Efficacy of treatment was calculated
as described in text. The p values for the comparison between mean # of worms recovered from control versus treated groups were as follows: KCW,
p=0.072; the sample size for KAS was too small to assess statistical significance; KNY, p,0.0001; PR1, p,0.0001; NMRI, p,0.0001. Error bars
correspond to standard error of the mean.
doi:10.1371/journal.pntd.0000504.g002
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from untreated control mice at both times were sexually mature,
and the livers from the mice harboring these infections contained
many granulomas. These results indicate that the reduced
susceptibility to PZQ observed in vivo with the KCW isolate was
not a result of delayed maturation rate of KCW worms.
In vitro effects of PZQ on adult worm length and survival
In the in vitro assay to test adult worm PZQ susceptibility (Figure 3)
we found that for all isolates, control worms not exposed to PZQ
remained elongated at all observation times and there were no
significant differences in worm length found among the three isolates
(p=0.678). Following exposure to PZQ, regardless of the dose
administered, worms from all three isolates contracted. However, for
worms that were treated with 80 mg/ml of PZQ, there were differences
among isolates in the extent that they remained contracted after the
24 hour recovery period. KNY and PR1 remained fully contracted
and did not move. These worms were considered dead as per the
definition of Pica-Mattoccia and Cioli [24]. In contrast, KCW worms
partially elongated and were moving and active, and had increased
their body lengths significantly more than KNY or PR1 worms
(p=0.038). Worms of all three isolates recovered their normal length if
they had been exposed to concentrations of PZQ lower than 80 mg/
ml. Conversely, doses higher than 80 mg/ml of PZQ were lethal for all
isolates.
Stability of the PZQ insensitive trait
After the initial in vitro assay of miracidia that indicated reduced
susceptibility of the KCW isolate, additional miracidia from this
patient were divided into two sub-isolates in 2005, one was
maintained in New Mexico and one in Kenya. After 8 generations
of passaging the Kenyan sub-isolate through mice and snails, we
performed the three susceptibility assays and found that the trait
for reduced susceptibility had been lost. Before splitting the KCW
isolate, in the in vitro assay of miracidia the mean percentage of
dead miracidia recorded was 11%, which was significantly lower
than after 8 generations (98%) and for all other isolates tested:
87%, 79%, 100%, and 78% for the PR1, NMRI, KAS and KSH
isolates, respectively (p,0.05). As shown in Figure 4, the subset of
KCW maintained for eight passages over three years in Kenya
(labeled KCW (2008)) showed no diminished susceptibility to PZQ
in the in vivo trials as compared to PR1 or KSH, and was
significantly more susceptible to PZQ than the New Mexico subset
of KCW (labeled KCW (2006) to indicate the year it was tested).
The in vitro test of adult worms showed similar results. The
difference in mean body length after the 24 hour recovery period
between the New Mexico KCW sub-isolate and PR1, KNY and
Kenyan KCW (2008) was significant (p=0.038). Kenyan KCW
(2008), PR1 and KNY did not differ in this regard (p=0.211). In
combination, these results indicate that the KCW sub-isolate
maintained in Kenya lost the trait of diminished sensitivity to PZQ
Figure 3. Photographs of S. mansoni adult worms of KNY (plate A) and KCW isolates (plate B), before exposure to PZQ (left column),
after 3 hrs of continuous exposure to PZQ (central column), and 24 hrs after removal from PZQ. Concentration of PZQ is shown on the
left side of the figure. The photographs show the effect of the drug on the length of the worms and the degree of recovery of the worm’s length after
removal from the sub-lethal concentrations of the drug. Note the difference in the response of the two isolates to the 8 mg/ml dose. The results for
the PR1 strain which was also tested were similar to those shown for the KNY isolate.
doi:10.1371/journal.pntd.0000504.g003
Praziquantel Tolerance in Schistosomes
www.plosntds.org 6 August 2009 | Volume 3 | Issue 8 | e504that we saw in miracidia when KCW was first isolated, and in
comparison to the New Mexico sub-isolate.
Discussion
In this study, we investigated PZQ susceptibility of S. mansoni
from a high-transmission endemic area [28,31] using in vitro assays
involving both miracidia and adult worms, and an in vivo assay
measuring drug susceptibility of adult schistosomes. In this
population, we found worms with reduced susceptibility to PZQ.
Miracidia collected from multiple patients varied significantly in
their susceptibility to PZQ, and this susceptibility was associated
with whether the patient had a history of exposure to the drug.
Miracidia from car washers were more tolerant to PZQ than those
from sand harvesters, which is not surprising because the car
washer focus had been studied since 1995, while the sand
harvesters were just being recruited in the study and had no prior
history of exposure to PZQ. These results may suggest population
level differences; however, we note that the sites are relatively close
(within 5 km of each other) and our ongoing population genetics
studies suggest no population subdivision between these groups or
any other schistosomes collected throughout the Kenyan portion
of Lake Victoria [22]. We hypothesize that treatment of individual
patients with PZQ led to the accumulation of resistant worms
within a single host rather than PZQ exposure inducing resistance
within a patient, although induction of hycanthone resistance in
schistosomes has been reported previously [37].
More in-depth studies were undertaken on an isolate (KCW)
established from a patient who yielded miracidia with relatively
low susceptibility to PZQ. Both in vivo and in vitro assays of adult
worms confirmed this observation and showed that they had
significantly lower susceptibility to PZQ than adults from other
recent Kenyan isolates or from lab stocks.
Drug resistance has evolved in many different microbial
pathogens and parasites [38,39], and is a looming concern for
control of any pathogen, including schistosomes. Vigilant
monitoring efforts are critical for preventing the spread and
controlling the problem of drug resistance. The in vitro assays
applied here were developed to monitor PZQ susceptibility of
schistosomes, and have been validated by demonstrating for a
variety of isolates that in vitro susceptibility of eggs, miracidia and
cercariae to PZQ correlate with in vivo susceptibility of adult worms
[26]. Such an in vitro assay is helpful given the inherent problems
with measuring PZQ efficacy in humans, which is determined by
measuring egg counts in fecal samples before and after treatment.
Such an indirect measurement of efficacy can lead to erroneous
conclusions about susceptibility of the schistosomes harbored by
the treated person: they may harbor immature worms not
susceptible to PZQ [16,34], re-infections are likely in endemic
areas and may confound interpretation of cure rates, and even
though egg counts have diminished they may still harbor mature
adult worms with temporarily inhibited egg production [40]. For
such reasons, in vitro assays to determine drug susceptibility can be
very useful, but they pose difficulties of their own. Most notably in
Figure 4. In vivo susceptibility to PZQ of adult worms. KCW (2008) refers to a subset of the KCW isolate kept in Kenya since 2005 that was
tested in 2008, after 3 years of passage in laboratory mice and snails in Kenya. KCW (2006) refers to a subset of the KCW isolate brought to New
Mexico in 2005 right after isolation from the patient, and that was tested in this assay in 2006. Also shown are results obtained with the KSH isolate
and the PR1 lab strain.
**Difference between average number of worms recovered from perfusion from control animals versus treated animal
significant (a=0.05). ET=Efficacy of treatment, was calculated as described in text.
doi:10.1371/journal.pntd.0000504.g004
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fecal samples which made it hard to perform in vitro assays on
populations of miracidia from some patients. Persistent difficulty in
getting eggs to hatch ultimately led to the loss of the KCW sub-
isolate maintained in New Mexico. Egg hatchability is an
understudied phenomenon that could play an important role in
the epidemiology of S. mansoni particularly if low hatching rates are
an associated cost of drug resistance.
Inclusion in our study of other Kenyan isolates that proved to be
susceptible to PZQ provides evidence of variable susceptibility in
natural populations and strengthens our findings of reduced
susceptibility because the laboratory stocks potentially could have
abnormal responses to praziquantel. Interestingly, the intensity of
infection achieved with the Kenyan isolates was lower than that
resulting from laboratory stocks. This difference likely is due to
host adaptation as the laboratory stocks have been maintained in
mice for several generations. It is unlikely that intensity influenced
the outcome of the in vivo trials as efficacy of treatment was
comparable across replicates regardless of intensity. In clinical
reports, high intensity sometimes correlates with reduced efficacy
of PZQ, but this could be due to high recruitment rates and the
presence of immature worms within the host, or merely be a
consequence of the fact that complete cures, as measured by
cessation of egg production, are harder to obtain in people with
high worm burdens even though the efficacy of treatment is the
same. Even if reduced efficacy with high intensity infections was a
phenomenon relevant to our in vivo trials, it would strengthen our
conclusions because our more susceptible worms were present in
higher intensities.
Worm maturation is a potential alternative explanation for our
results if the KCW worms develop more slowly in mice such that
they were still immature and thus less susceptible to PZQ at
standard treatment times. Although we saw no consistent evidence
of a slower development rate, and KCW worms recovered upon
perfusion at 7.5 weeks post-infection were mature, we nonetheless
addressed this possibility in an experiment that allowed three
weeks of additional development before treatment was adminis-
tered. The low PZQ susceptibility of these older, fully mature
worms renders any argument invoking slower development times
an unlikely explanation for the low PZQ susceptibility of KCW
worms.
In our study, diminished susceptibility to PZQ was a heritable
trait that persisted across multiple generations: the KCW sub-
isolate maintained in New Mexico retained reduced PZQ
susceptibility over 6 generations, even in the absence of drug
pressure. However, for the KCW sub-isolate maintained in Kenya,
this trait was lost sometime during 8 generations of laboratory
rearing. Loss of diminished susceptibility traits has also been
reported for Egyptian field isolates brought into the laboratory
[41]. The relative ease with which the trait of reduced PZQ
susceptibility was lost may be associated with a fitness cost such as
diminished asexual reproductive capacity in snails [41]. Fitness
costs have been noted in other drug resistant organisms and play a
large role in their evolution [42]. It is also interesting that with our
divided isolates of KCW, the drug tolerant sub-isolate perished,
but the susceptible sub-isolate persisted.
The data from this study suggest that at least some members of
the S. mansoni population in the Lake Victoria region have lower
susceptibility to PZQ. As with most anthelmithic resistance, it is
assumed that this trait has occurred naturally within the
population even prior to drug treatment in the region. In fact,
the patient from whom the KCW isolate was derived was never
fully cured, even after the very first treatment. Furthermore, a
longitudinal epidemiological study of these patients over the course
of 12 years reported an average cure rate of 66%, but no evidence
of increased treatment failure or clinically relevant level of
resistance over the course of the study [28]. These findings suggest
that worms with reduced susceptibility to praziquantel occur in the
population, and are more common in patients that have been
repeatedly treated, but this trait remains in relatively low
frequency throughout the entire worm population. We suggest
two hypotheses for this observation. First, although drug pressure
is strong on the select target group of patients in Kisumu, the
overall population of S. mansoni in snails, humans and other
mammals in the Lake Victoria basin is vast [31], leaving a large
refugium of untreated worms that are not subject to selection.
Therefore, after treatment, the frequency of resistance alleles
would remain low in the remaining worm population and likely in
subsequent generations. The size of the untreated refugium has
been shown to play an important role controlling the spread of
resistance to other anthelminthics [43]. A second factor is that
there may be a fitness cost associated with resistance, which would
also work to prevent accumulation of the trait in the population
unless the benefits of resistance outweighed the costs [41]. This
reality, one that likely applies in many schistosomiasis endemic
areas in Africa where treatment programs are underway, lessens
current concerns about the spread of PZQ-resistance. However, as
treatment expands to an ever larger proportion of infected
individuals, then the refugia for unexposed parasites will diminish
in size, increasing the chances for resistance to emerge.
One of the most concerted programs of PZQ treatment,
directed against S. haematobium in coastal Kenya, found variability
in responsiveness to the drug, but no evidence of progressive
emergence of PZQ resistance over an 8 year interval [19].
However, this program also involved a large refugium of untreated
schistosomes because treatment was targeted to school children,
and as the authors note, the limited coverage of the program may
have reduced the tendency for resistance to spread. Based on
computer modeling, it was predicted that emergence of PZQ
resistance in this region should be anticipated within 10 to 20 years
of its continued massive use [19].
Three aspects pertaining to the potential emergence of PZQ
resistance are particularly deserving of additional study. The first is
to determine if repeated cycles of infection and treatment of a
single patient can favor the accumulation of a subset of S. mansoni
adults more tolerant to PZQ and through recombination of alleles
due to sexual reproduction, can lead to enhanced resistance in
offspring. The pattern of decreased responsiveness to PZQ of
miracidia derived from patients that had received multiple
treatments, including KCW, is compatible with such a possibility.
Trials to assess the safety and efficacy of higher doses for patients
that fail to cure following exposure to standard PZQ dosages, or
approval of more widespread availability of alternative treatments,
such as oxamniquine, may both be prudent considerations when
treatment failures occur. Second, because we lack a fundamental
understanding of PZQ’s mode of action, we are also ignorant of
the natural variability in PZQ’s targets in schistosome populations
in endemic areas. It will be important to determine if variants
inherently less susceptible to PZQ’s effects are particularly likely to
occur in the large, genetically diverse populations of species like S.
mansoni [23] that still thrive throughout much of sub-Saharan
Africa. More explicit knowledge of PZQ’s targets will help us to
devise much-needed improved assays for monitoring the emer-
gence of resistance. Third, methods for genotyping individual eggs
or miracidia need to be used to determine if the worm populations
harbored by people before and after treatment show evidence of
strong similarity, suggestive of the retention of fully adult worms
that are not killed but merely temporarily silenced by PZQ
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negative for egg passage for long periods indicating they have been
successfully cured and may even have acquired effective resistance
to reinfection [30], but others resume egg production after
treatment, indicative of acquisition of new worms, or possibly
reactivation of existing worms.
We conclude by noting that, ironically, the maintenance of
PZQ susceptibility may come at the expense of poor coverage and
continued high transmission. Continued monitoring of PZQ
susceptibility using assays such as the ones employed here, and
new and improved assays, is warranted as increased use of PZQ in
control programs becomes a reality.
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